Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 12/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 3/20 | 0.36 |
| ▸ | PRKCI | P41743 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2976805 | 0.91 | PRKCI (0.44) | FGFR1SRCPRKCIMAPK1SMN1; SMN2 | |
| SCHEMBL2974092 | 0.91 | FGFR1 (0.38) | FGFR1SRCPRKCIMAPK1SMN1; SMN2 | |
| SCHEMBL2963434 | 0.87 | SIGMAR1 (0.38) | FGFR1KDRSMN1; SMN2GABRA1GABRG2 | |
| SCHEMBL2966390 | 0.86 | FGFR1 (0.44) | FGFR1SRCPRKCIMAPK1SMN1; SMN2 | |
| SCHEMBL2652696 | 0.84 | FGFR1 (0.36) | FGFR1SRCPRKCIMAPK1SMN1; SMN2 | |
| SCHEMBL2977952 | 0.84 | HPGD (0.37) | FGFR1KITFLT3SRCKDR | |
| SCHEMBL2659958 | 0.84 | PRKCI (0.35) | FGFR1SRCPRKCIMAPK1SMN1; SMN2 | |
| SCHEMBL2964600 | 0.82 | HPGD (0.45) | FGFR1MAPK1SMN1; SMN2GABRA1GABRG2 | |
| SCHEMBL2641993 | 0.76 | KDR (0.57) | FGFR1KITFLT3SRCKDR | |
| SCHEMBL2652685 | 0.75 | GABRA1 (0.47) | FGFR1KITFLT3SRCKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776900-B2 | Benzimidazole derivatives and their use for modulating the GABAAreceptor complex | NEUROSEARCH A/S (DK) | 2010-08-17 | — | — | US | claimed |
| US-20090030018-A1 | Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex | ANIONA APS (DK) | 2009-01-29 | — | — | US | claimed |
| US-7776900-B2 | Benzimidazole derivatives and their use for modulating the GABAAreceptor complex | NEUROSEARCH A/S (DK) | 2010-08-17 | — | — | US | disclosed |
| US-20090030018-A1 | Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex | ANIONA APS (DK) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030018-A1 | Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex | GABRB2, GABRB1, GABRB3 | FGFR1 4324/4885KIT 3187/4885FLT3 2451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.